Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands
Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions
How this was made
The 30-second read
Why it matters
The guidance and acquisition updates provide fresh insight into growth trajectory and cash‑flow outlook.
Market read
First report of 2026 guidance and recent acquisitions offers actionable data for investors in VMD and sector peers.
What to watch
Potential impact of GLP‑1 drugs on sleep‑therapy demand and future debt‑financed acquisitions.
Background
Viemed Healthcare provides home‑based respiratory therapy, recently expanded via acquisitions and new product lines.
Ticker impact
Company issued 2026 revenue guidance of $317M and low‑20% growth, plus disclosed recent acquisitions and capital allocation plans.
Potential modest upside if guidance beats market expectations; downside risk if growth slows.
First disclosure of full‑year guidance and acquisition activity provides fresh data for valuation models.
Market effects
Highlights growth in home respiratory therapy and sleep‑therapy markets, may benefit peers.
Focus on U.S. home‑care services; limited broader regional effect.
Limited to U.S. healthcare equipment sector.
Counterpoint
Guidance may be overly optimistic given capital intensity and margin pressure from new lines.
Key entities
- ExecutiveTodd Zehnder
Chief Operating Officer, provided guidance and capital allocation comments.
- Acquired CompanyLehan's
Recent acquisition adding respiratory and maternal health capabilities.
